TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 11/01/22

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated with TFF VORI Recently Presented at the 15th Annual International Congress on Lun...

FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announc...

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aeros...

FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announ...

Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aerosol Performa...

The following slide deck was published by TFF Pharmaceuticals, Inc. in conjunction with this event. For further details see: TFF Pharmaceuticals (TFFP) Investor Presentations - Slideshow

Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient Patient previously intolerant to oral voriconazole therapy successfully treated with TFF VORI...

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announ...

Summary While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these. These partnerships are mostly in the pre-clinical phase and are unlikely to lead to near-time monetization. For...

Image source: The Motley Fool. TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TFF Pharmaceuticals, Inc. (TFFP) Q2 2022 Earnings Call Transcript...